GLP-1 and metabolic research peptides

About glp-1 and metabolic research peptides

The incretin peptides are the most heavily studied group in current metabolic research. They act on receptors that regulate glucose handling and energy balance, and the research literature separates them by which receptors each one engages rather than by any claimed outcome.

Retatrutide is a triple agonist, engaging GLP-1, GIP and glucagon receptors. Tirzepatide engages the first two. Cagrilintide works through the amylin receptor instead, which is why published protocols sometimes study amylin and incretin compounds side by side rather than treating them as substitutes. AOD-9604 is a growth-hormone fragment studied on a different axis again.

For procurement, the practical difference between these compounds is documentation rather than chemistry. Each is supplied lyophilised, each carries a batch-specific certificate of analysis with an HPLC purity figure and a mass-spectrometry identity result, and each is dispatched from Australian stock. Where a compound is offered in more than one strength, each strength is a separately analysed batch with its own certificate.

All compounds listed are supplied for in vitro laboratory and educational research only. They are not listed on the Australian Register of Therapeutic Goods (ARTG) and are not for human or animal consumption.